Regional Medicines Optimisation Committee FreeStyle Libre Position Statement

NHS England clinical guidance for the monitors has now been published, outlining funding arrangements for local health groups and the criteria for who qualifies for the technology. NHS England National Clinical Directors reviewed the RMOC FreeStyle Libre guidance and amended it based on their input and their diabetes network’s input. RMOCs members had an opportunity to comment on the draft criteria and those comments were fed into the process for defining the new commissioning guidance.

From April, the NHS will provide the technology for one in five of those with Type 1 diabetes. Those who qualify include:

  • People with Type 1 diabetes who need intensive monitoring (more than 8 times every day) as demonstrated in a review over the past 3 months
  • People with Type 1 diabetes associated with cystic fibrosis on insulin treatment
  • Pregnant women with Type 1 Diabetes – 12 months in total inclusive of post-delivery period
  • People with Type 1 diabetes unable to routinely self-monitor blood glucose due to disability
  • People with Type 1 diabetes for whom the specialist diabetes MDT determines have occupational or psychosocial circumstances that warrant a 6-month trial of Libre with appropriate support

You can read the full story and guidance in here.

If you have any queries regarding the new guidance, please contact –

Acute CareNewsPolicy, Commissioning and ManagerialPrimary CareRMOC medicines optimisation recommendations and resources